Fact sheet Lenacapavir and long-acting injectable PrEP

The Information Sheet on Lenacapavir and Long-Acting Injectable PrEP provides a clear and up-to-date overview of this new HIV prevention tool. Its purpose is to explain, in simple terms, how the medication works, who can benefit from it, and why it represents an important advancement in HIV prevention.

The material outlines the key features of Lenacapavir, including its twice-yearly administration schedule, and how it complements existing PrEP options such as daily oral PrEP and other injectable formulations. It also highlights its recent inclusion in WHO guidance and its approval by the U.S. FDA, underscoring its safety and effectiveness.

This information sheet supports health professionals, communicators, and communities in better understanding this biomedical innovation, strengthening prevention strategies, and helping expand access to diversified care options.